Clinical Trial Detail

NCT ID NCT01779050
Title Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Washington University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Trastuzumab

Docetaxel

Epirubicin + Cyclophosphamide

Paclitaxel

Fluorouracil + Epirubicin + Cyclophosphamide

Docetaxel + Carboplatin

Docetaxel + Cyclophosphamide

Age Groups: adult

Additional content available in CKB BOOST